Whole-body Tumor Infiltrating Lymphocytes Biodistribution Imaging

Another new proprietary single-domain antibody based radiotracer independently developed by SmartNuclide Biopharma used to non-invasively image whole-body density and distribution of Tumor Infiltrating Lymphocytes (TIL) in cancer patients. Studies have shown that tumor infiltration via TIL is strongly associated with favorable outcomes to immunotherapy, thus became a clinically crucial indicator in immunotherapy for early prediction of therapeutic response of immune checkpoint inhibitors and prediction of effectiveness of immune agonist agents.

SNA006 is designed to be used with PET scan technology for a non-invasive whole-body view of immune system activity to select the right patients for immunotherapies, as well as to evaluate whether cancer patients’ immune systems respond efficaciously to immunomodulatory agents, that is crucial to better understand and rationally develop next-generation immunotherapies. PET scan imaging can be taken within just about 2 hours after the infusion of the radiotracer.